Your browser doesn't support javascript.
Prevalence of Asymptomatic SARS-CoV-2 Infection in the General Population of the Veneto Region: Results of a Screening Campaign with Third-Generation Rapid Antigen Tests in the Pre-Vaccine Era.
Cocchio, Silvia; Nicoletti, Michele; De Siena, Francesco Paolo; Lattavo, Gaia; Furlan, Patrizia; Fonzo, Marco; Tonon, Michele; Zabeo, Federico; Russo, Francesca; Baldo, Vincenzo.
  • Cocchio S; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • Nicoletti M; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • De Siena FP; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • Lattavo G; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • Furlan P; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • Fonzo M; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • Tonon M; Regional Directorate of Prevention, Food Safety, Veterinary Public Health-Regione del Veneto, 30123 Venice, Italy.
  • Zabeo F; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
  • Russo F; Regional Directorate of Prevention, Food Safety, Veterinary Public Health-Regione del Veneto, 30123 Venice, Italy.
  • Baldo V; Department of Cardiac Thoracic and Vascular Sciences, and Public Health, University of Padua, 35131 Padua, Italy.
Int J Environ Res Public Health ; 18(20)2021 10 15.
Article in English | MEDLINE | ID: covidwho-1470855
ABSTRACT
The aim of our study was to ascertain the prevalence of SARS-CoV-2 infection in the general population during a period of moderate risk, just before Italy started to implement its vaccination campaign. A third-generation antigenic nasal swab sample was collected by a healthcare provider, and all individuals testing positive subsequently had a nasopharyngeal swab for molecular testing; the result was used to calculate the positive predictive value. The population consisted of 4467 asymptomatic adults with a mean age of 46.8 ± 16.00 years. The 62.2% tested for the first time, while 37.8% had previously undergone a mean 2.2 tests for SARS-CoV-2. With 77 of our overall sample reporting they had previously tested positive for COVID-19 and 14 found positive on our screening test, the overall estimated prevalence of the infection was 0.31%. Nine of the 14 cases were confirmed on molecular testing with a PPV of 64.3%. The mean age of the individuals testing positive was 38.1 ± 17.4. Based on the timing of symptom onset, six of the above cases were classified as false negatives, and the adjusted estimated prevalence was 0.34%. Describing levels of infection in a general population seems to be very difficult to achieve, and the universal screening proved hugely expensive particularly in a low-prevalence situation. Anyway, it is only thanks to mass screening efforts that epidemiological data have been collected. This would support the idea that routine screening may have an impact on mitigating the spread of the virus in higher-risk environments, where people come into contact more frequently, as in the workplace.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Adult / Humans / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Ijerph182010838

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Adult / Humans / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Ijerph182010838